PMID- 23449041
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130304
LR  - 20240321
IS  - 1389-2029 (Print)
IS  - 1875-5488 (Electronic)
IS  - 1389-2029 (Linking)
VI  - 13
IP  - 6
DP  - 2012 Sep
TI  - On the Power of Additional and Complex Chromosomal Aberrations in CML.
PG  - 471-6
LID - 10.2174/138920212802510466 [doi]
AB  - Unregulated proliferation of mainly myeloid bone marrow cells and genetic changes 
      in the hematopoietic stem cell system are important features in Chronic Myeloid 
      Leukemia (CML). In clinical diagnosis of CML, classical banding techniques, 
      fluorescence in situ hybridization (FISH) probing for the Philadelphia chromosome 
      (Ph) or polymerase chain reaction amplifying the fusion products of the BCR-ABL 
      fusion are state of the art techniques. Nevertheless, the genome of CML patients 
      harbors many more cytogenetic changes. These might be hidden in subpopulations 
      due to clonal events or involved in extremely complex aberrations. To identify 
      these additional changes, several cytogenetic and molecular genetic techniques 
      could be applied. Nevertheless, it has been proposed that identifying these 
      aberrations is time consuming and costly and since they cannot be converted into 
      a benefit for the patients, the necessity to perform these investigations has 
      been questioned. In the times where highly specialized medicine is advancing into 
      several areas of cancer, this attitude needs to be reassessed. Therefore, we 
      looked at the usefulness of a combination of different techniques to unravel the 
      genetic changes in CML patients and to identify new chromosomal aberrations, 
      which potentially can be correlated to different stages of the disease and the 
      strength of therapy resistance. We are convinced that the combination of these 
      techniques could be extremely useful in unraveling even the most complex 
      karyotypes and in dissecting different clones contributing to the disease. We 
      propose that by doing so, this would improve CML diagnostic and prognostic 
      findings, especially with regard to CML resistance mechanisms and new therapeutic 
      strategies.
FAU - Greulich-Bode, Karin M
AU  - Greulich-Bode KM
AD  - Division Genetics of Skin Carcinogenesis, German Cancer Research Center (DKFZ), 
      D-69120 Heidelberg, Germany.
FAU - Heinze, Barbara
AU  - Heinze B
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Genomics
JT  - Current genomics
JID - 100960527
PMC - PMC3426781
OTO - NOTNLM
OT  - Breakpoints
OT  - CGH translocation
OT  - CML
OT  - Clinical impact.
OT  - Complex aberrations
OT  - Cytogenetics
OT  - Fish
EDAT- 2013/03/02 06:00
MHDA- 2013/03/02 06:01
PMCR- 2013/03/01
CRDT- 2013/03/02 06:00
PHST- 2012/04/29 00:00 [received]
PHST- 2012/05/24 00:00 [revised]
PHST- 2012/06/13 00:00 [accepted]
PHST- 2013/03/02 06:00 [entrez]
PHST- 2013/03/02 06:00 [pubmed]
PHST- 2013/03/02 06:01 [medline]
PHST- 2013/03/01 00:00 [pmc-release]
AID - CG-6-471 [pii]
AID - 10.2174/138920212802510466 [doi]
PST - ppublish
SO  - Curr Genomics. 2012 Sep;13(6):471-6. doi: 10.2174/138920212802510466.